Novo Nordisk A/S Rotten Score Breakdown
Corporate Misconduct
30.0ptsRotten to the core
Avg Rating: 5.00Ratings: 1Severity Score: 6.00Evidence Count: 1Contribution: 30.0 pts
Misconduct: low 0 · medium 0 · high 1
Remediation: low 0 · medium 0 · high 0ⓘ cap: 25%
Novo Nordisk USD 58.65 million Victoza REMS and False Claims settlement
Novo Nordisk agreed to pay USD 58.65 million in 2017 to resolve U.S. allegations that its U.S. subsidiary failed to comply with an FDA-mandated Risk Evaluation and Mitigation Strategy for the diabetes drug Victoza and related False Claims Act allegations. The resolution included USD 12.15 million in disgorgement tied to alleged FDCA violations from 2010 to 2012 and USD 46.5 million relating to alleged False Claims Act violations from 2010 to 2014. Source: https://www.justice.gov/archives/opa/pr/novo-nordisk-agrees-pay-58-million-failure-comply-fda-mandated-risk-program
Human Rights & Exploitation
0.0ptsNo documented evidence
Avg Rating: —Ratings: 0Severity Score: 0.00Evidence Count: 0Contribution: 0.0 pts
Fraud & Corruption
0.0ptsNo documented evidence
Avg Rating: —Ratings: 0Severity Score: 0.00Evidence Count: 0Contribution: 0.0 pts
Deceptive Practices
0.0ptsNo documented evidence
Avg Rating: —Ratings: 0Severity Score: 0.00Evidence Count: 0Contribution: 0.0 pts
Environmental Harm
0.0ptsNo documented evidence
Avg Rating: —Ratings: 0Severity Score: 0.00Evidence Count: 0Contribution: 0.0 pts
Sustainability Deception
0.0ptsNo documented evidence
Avg Rating: —Ratings: 0Severity Score: 0.00Evidence Count: 0Contribution: 0.0 pts
Workplace Misconduct
0.0ptsNo documented evidence
Avg Rating: —Ratings: 0Severity Score: 0.00Evidence Count: 0Contribution: 0.0 pts
Financial Misconduct
0.0ptsNo documented evidence
Avg Rating: —Ratings: 0Severity Score: 0.00Evidence Count: 0Contribution: 0.0 pts